IMNM Company Profile and Key Details

Immunome, Inc. (NASDAQ:IMNM) closed at $21.64 USD, gaining $0.20 (0.96%) from the previous close of $21.44. The stock is currently mid-range between its 52-week high and low $5.15 and $25.30. With a market capitalization of about $1.98 billion, Immunome, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~2.18). Key stats such as the average daily volume over the past year has been around 1.93 million shares, volume is running light vs its 52-week average. Headquartered in Bothell, PA, Immunome, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Clay Siegall, the company employs approximately 131 people and listed since October 02, 2020. Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease.

IMNM has shown sold momentum, gaining 10.01% over the past week and 128.33% over the past quarter, though year-to-date performance is up 101.88%. Short-term trend indicators are bearishly aligned (SMA20 9.25%, SMA50 21.89%, SMA200 90.07%). The stock’s 14-day RSI is 58.96 (neutral), while the ATR of 1.7 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -15.26% below its high and over 316.3% above its low. Average 10-day trading volume of 7.18 million shares is significantly above the 3-month average of 1.87 million, indicating heightened recent market interest.

Immunome, Inc. has 87.05 million shares outstanding. The public float is 70.81 million shares, elevated short interest at 17.06% of float. This equals 14.21 million shares. The short ratio is 12.83 days. Institutional investors hold 98.22% of the float. Insiders own 11.47%. SIEGALL CLAY B holds 853.25 thousand shares, WAGENHEIM PHILIP has 397.40 thousand shares and RAPP MICHAEL has 208.74 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Immunome, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.43. This means the shares are trading above this model’s fair value.

Immunome, Inc. generated EPS of -$2.96 over the past year. Five-year average earnings growth is -38.15%. Wall Street analysts project EPS growth of 22.95% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 6 Strong Buy ratings, 8 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $40.00 to $18.00. The high target offers 86.57% upside. The low target suggests -16.04% downside. The mean target is $28.86. This offers 34.61% upside. Immunome, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by 14.04%. The prior quarter beat by -3.85%. Over the last six quarters, Apple has recorded several small beats. These include 28.95% in August 12, 2024.

Our AI price prediction model suggests that Immunome, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 7.7%, with price expected at $23.09 by January 02, 2026, within a range of $22.02 to $24.17 3-Month Outlook: Projected rise of 118.66%, reaching $46.88 by March 19, 2026, with a range of $46.30 to $47.80. 1-Year Outlook: Projected gain of 8.3%, with price at $23.22 by December 18, 2026, within a range of $21.36 to $24.88.

Immunome, Inc. (NASDAQ:IMNM) shares are up 101.88% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Immunome, Inc. trading at a premium to the broader market with a P/E of -8.78. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $26.50, suggesting 23.6% upside. Our AI forecast model points to short-term strength (7.7% over two weeks), a medium-term rise (118.66% over three months), and a longer-term gain (8.3% over one year), with expected trading ranges indicating moderate volatility.

Immunome, Inc. trades at a P/E ratio of -8.78, slightly below the S&P 500 average, with a price-to-sales ratio of 156.18 and a price-to-book ratio of 6.93 trading at moderately above to book value. The P/FCF stands at -10.56, also below market averages.